Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2009
10/13/2009US7601701 Compounds for the treatment of tobacco dependence and withdrawal
10/13/2009US7601700 Modified antisense oligonucleotide; antitumor and anticancer agents
10/13/2009US7601696 Oct-1 as an oncoprotein and use of nucleic acid inhibitors of Oct-1 for cancer treatment
10/13/2009US7601695 11-N-[4-(4-Pyridin-3-yl-imidazol-1-yl)-butyl]-6-O-methyl-5-O-(3-dimethylamino-2-hydroxy-propoxy)-3-oxo-erythronolide A, 11,12-carbamate; functionalized macrolides; antiviral, antiprotozoal, anticancer and antigastrointestinal
10/13/2009US7601690 Cross-linked glycopeptide-cephalosporin antibiotics
10/13/2009US7601523 Method for production of arachidonic acid
10/13/2009US7601508 Ecdysone receptor polypeptide from the homopteran whitefly (Bamecia argentifoli, BaEcR) use screening for monoclonal antibodies; biological insecticides
10/13/2009US7601488 Hyaluronic acid oligosaccharide fractions and drugs containing the same
10/13/2009US7601369 Composition and method to augment and sustain neurotransmitter production
10/13/2009US7601367 Delivering a siRNA to a mammal cell; low toxicity
10/13/2009US7601364 Carbohydrate mixtures
10/13/2009US7601360 Excitatory amino acid inhibitors for treating sensitive skins
10/13/2009US7601359 Compositions and methods for the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress proteins
10/13/2009US7601354 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
10/13/2009US7601343 An isolated RNA-pulsed antigen presenting cell comprising tumor specific RNA; stimulation of cytotoxic T-lymphocyte proliferation ex vivo or in vivo for adoptive immunotherapy; anticarcinogenic agents; antitumor agents; bactericides; viricides
10/13/2009US7601338 Dentifrice and mouthwash compositions comprising an enzyme having waterinsoluble impurities and a cyclodextrin which complexes with the impurity to form a waterform an insoluble complex; papain or other proteolytic enzymes; impurities including lipohilic and sulfur compounds;ketones; organoleptic
10/13/2009US7601337 Delivery of antipsychotics through an inhalation route
10/13/2009US7601212 polysaccharide coating selected from ionic natural polysaccharides and ionic derivatives of natural polysaccharides, titanium dioxide particles comprising a surface treatment material selected from aluminum phosphate, alkyltrialkoxysilanes, aluminum phosphte, 3-aminopropyltriethoxysilane; for paper
10/13/2009US7601157 Devices and methods for the restoration of a spinal disc
10/13/2009CA2602188C Dosage forms of risedronate
10/13/2009CA2560510C N-(1-arylpyrazol-4yl) sulfonamides and their use as parasiticides
10/13/2009CA2521846C Reverse-turn mimetics and method relating thereto
10/13/2009CA2482405C Multiple compartment bag assembly for dialysis fluid
10/13/2009CA2473070C Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection
10/13/2009CA2472373C Combination of paclitaxel and a polymer
10/13/2009CA2471666C An improved process for the preparation of oxcarbazepine and related intermediates
10/13/2009CA2470484C A combination comprising combretastatin and anticancer agents
10/13/2009CA2455298C Condensed polycyclic compounds
10/13/2009CA2455246C Drug preparation comprising .alpha.-lipoic acid, ambroxol and/or inhibitors of the angiotensin-converting enzyme (ace) and its use for the treatment of neurodegenerative diseases
10/13/2009CA2454022C Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for treatment of osteoporosis
10/13/2009CA2449572C 4'-substituted nucleosides
10/13/2009CA2447807C Abuse resistant pharmaceutical composition containing capsaicin
10/13/2009CA2445276C Aripiprazole oral solution
10/13/2009CA2438910C Amphoteric sterols and the use thereof in the production of ph-sensitive liposomes
10/13/2009CA2429844C Mch antagonists and their use in the treatment of obesity
10/13/2009CA2428160C Compositions for antitumor treatment containing ecteinascidin 743
10/13/2009CA2419471C Use of triazinetrione sulphones for controlling coccidioses
10/13/2009CA2419416C Tetrazolyl-phenyl acetamide glucokinase activators
10/13/2009CA2414665C Rapidly disintegrating dosage form for releasing active ingredients in the oral cavity or in body cavities
10/13/2009CA2408716C Stable polymeric micelle-type drug composition and method for the preparation thereof
10/13/2009CA2403286C Cholesterol sulfate and amino sugar compositions for enhancement of stratum corneum function
10/13/2009CA2396093C Process and composition for controlling fecal hair excretion and trichobezoar formation
10/13/2009CA2395866C Ophthalmic anti-allergy compositions suitable for use with contact lenses
10/13/2009CA2392620C Use of melatonin for the treatment of androgenetic and diffuse alopecia
10/13/2009CA2386974C Benzodiazepine derivatives for use in acute or chronic neurological disorders
10/13/2009CA2384037C Pyrazolo[4,3-d]pyrimidines
10/13/2009CA2379666C Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof
10/13/2009CA2373867C Compositions comprising organosiloxane resins for delivering oral care substances
10/13/2009CA2370830C Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors
10/13/2009CA2370388C Crystalline forms of the sodium salt of 5-chloro-2-methoxy-n-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonylphenyl)ethyl)benzamide
10/13/2009CA2368274C C10 ester substituted taxanes as antitumor agents
10/13/2009CA2367615C Transdermal therapeutic system with nicotine and addition of monoterpene ketones
10/13/2009CA2351463C Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
10/13/2009CA2341678C Potassium channel inhibitors and method
10/13/2009CA2334775C Benzo(b)thiepine-1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
10/13/2009CA2322311C Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
10/13/2009CA2321265C Antibacterial compositions with synergistic effect, drugs and remedies for digestive diseases containing the same, process for the production thereof and preparations associated therewith
10/13/2009CA2319515C Anhydrous topical skin preparations
10/13/2009CA2318512C Transfecting compositions sensitive to reducing conditions, pharmaceutical compositions containing them, and their applications
10/13/2009CA2292775C Cyanoguanidines as cell proliferation inhibitors
10/13/2009CA2291218C Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnf.alpha. levels
10/13/2009CA2264552C Method of using tetracycline compounds for inhibition of nitric oxide production
10/13/2009CA2236888C Medicament, in particular for modulation of the immune response in the control of viruses, tumors, bacteria and parasites
10/13/2009CA2234263C Pharmaceutical composition for treating papillomavirus tumours and infection
10/13/2009CA2224413C Immunovectors for the intracellular and intranuclear transport
10/13/2009CA2222650C Tnf-.alpha. converting enzyme
10/13/2009CA2180810C Stable gelatin coated acetylsalicylic acid tablets
10/13/2009CA2154488C Ganglioside-klh conjugate vaccines with qs-21
10/13/2009CA2110291C Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
10/13/2009CA2092271C Use of g-csf for treating taxol side-effects
10/10/2009CA2627021A1 Combination natural source/local anesthetic/dual component penetration enhancer topical formulation useful for treating pain, itching and/or inflammation of the skin
10/09/2009CA2659498A1 American cranberry extract and use
10/08/2009WO2009124300A2 Solid state forms of a pharmaceutical
10/08/2009WO2009124295A2 Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
10/08/2009WO2009124266A2 Alkylated sem-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
10/08/2009WO2009124259A1 Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors
10/08/2009WO2009124252A2 Methods and compositions for the treatment of rheumatoid arthritis and other inflammatory diseases
10/08/2009WO2009124238A1 Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
10/08/2009WO2009124237A1 Halichondrin b analogs
10/08/2009WO2009124184A2 Methods of activating rnase l
10/08/2009WO2009124175A1 Formulations comprising a phosphoindole compound and one or more second active agents
10/08/2009WO2009124167A1 Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
10/08/2009WO2009124166A1 Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
10/08/2009WO2009124103A2 Combination therapies comprising par1 antagonists with par4 antagonists
10/08/2009WO2009124086A2 Antibacterial drug for treatment of staphylococcus aureus and other gram-positive bacterial infections
10/08/2009WO2009124037A1 Processes for preparing sunitinib and salts thereof
10/08/2009WO2009124024A1 Compositions and methods for inhibition of hepatocyte growth factor receptor c-met signaling
10/08/2009WO2009124022A1 2 -aminotetralin derivatives as mu opioid receptor antagonists
10/08/2009WO2009124013A1 Compositions and mehtods for inhibition of hepatocyte growth factory receptor c-met signaling
10/08/2009WO2009123992A1 Oxymethylene aryl compounds and uses thereof
10/08/2009WO2009123986A1 Apoptosis signal-regulating kinase 1 inhibitors
10/08/2009WO2009123971A1 Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use
10/08/2009WO2009123967A1 5,6,7,8-tetrahydroquinazolin-2-amine derivatives and related compounds as histamine h4 receptor modulators for the treatment of asthma
10/08/2009WO2009123948A2 Compounds and compositions as itpkb inhibitors
10/08/2009WO2009123896A1 Pyridyl derivatives as cftr modulators
10/08/2009WO2009123881A1 Purine derivatives as a3 receptor- selective agonists
10/08/2009WO2009123877A1 A method of treating a nervous system disorder by modulation of neurogenesis with mcc-257
10/08/2009WO2009123876A1 Storage-stable polymaleimide prepolymer compositions
10/08/2009WO2009123870A1 Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
10/08/2009WO2009123855A1 3-indazolyl-4-pyridylisothiazoles
1 ... 2542 2543 2544 2545 2546 2547 2548 2549 2550 2551 2552 2553 2554 2555 2556 2557 2558 2559 2560 2561 2562 ... 7860